This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.
Zimmer Biomet's FDA 510(k) Nod Widens Robotic Offerings
by Zacks Equity Research
With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.
Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm
by Zacks Equity Research
Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.
National Vision (EYE) Rides on Positive Comps Amid Cost Woes
by Zacks Equity Research
National Vision (EYE) has been witnessing positive comps owing to increased customer transaction over the last 68 sequential quarters.
STERIS (STE) Margin Pressure Hurts, Strategic Growth High
by Zacks Equity Research
Mounting operating expenses are weighing on the bottom line of STERIS (STE).
TeleFlex Announces Multiple Positive Outcomes on UroLift
by Zacks Equity Research
A study by TeleFlex (TFX) sheds light on the real-world retrospective data on 30 men suffering urinary retention treated with the UroLift System.
Abbott (ABT) Gains Ground on Solid EPD and Diabetes Arms
by Zacks Equity Research
Abbott's (ABT) EPD business operates in emerging geographies like India, Russia, China and Latin America.
Phibro Animal Solid on Global Prospects, Currency Woes Ail
by Zacks Equity Research
Phibro Animal (PAHC) has been gaining from strong volume growth in foreign markets. However, adverse currency movements remain a concern.
Henry Schein's New Buyout to Boost Dental Technology Business
by Zacks Equity Research
Henry Schein (HSIC) expects the acquisition to be neutral to its 2019 earnings per diluted share and accretive thereafter.
Zimmer Biomet Solid on Global Prospects Despite Price Pressure
by Zacks Equity Research
Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.
Myriad's myPath Melanoma Test Awarded Medicare Coverage
by Zacks Equity Research
The latest nod from Medicare Coverage for Myriad's (MYGN) myPath Melanoma test is likely to boost top-line results in the near term.
Align Technology (ALGN) Partners With Digital Smile Design
by Zacks Equity Research
Align Technology (ALGN) will be integrating Digital Smile Design's methodology in functional and aesthetic dentistry with its end-to-end digital workflow covering iTero scanners and Invisalign system.
Boston Scientific's WATCHMAN FLX LAAC Device Gets CE Mark
by Zacks Equity Research
Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.
HOLX vs VAR: Which MedTech Stock is a Better Investment Pick?
by Zacks Equity Research
Hologic (HOLX) looks stronger than Varian Medical (VAR) when it comes to current-year earnings projections as well as fundamentals.
QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test
by Zacks Equity Research
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) is currently focusing on improving clinical quality.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Bio-Rad (BIO) seeing solid revenue growth in geographies like Americas and Asia Pacific buoys optimism.
HOLX vs DXCM: Which MedTech Stock is a Better Investment Pick?
by Zacks Equity Research
DexCom (DXCM) looks stronger than Hologic (HOLX) when it comes to current-year earnings and revenue projections as well as fundamentals.
Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now
by Zacks Equity Research
Hologic's (HOLX) management is impressed with continued growth in the core Molecular Diagnostics sub-segment.
Hologic (HOLX) Receives Global Nods for Omni Hysteroscope
by Zacks Equity Research
Hologic's (HOLX) receipt of approvals for Omni Hysteroscope in Canada and Europe is expected to boost the GYN Surgical arm.
Here's Why Momentum Investors Will Love Hologic (HOLX)
by Zacks Equity Research
Does Hologic (HOLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Hologic's (HOLX) Q1 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Hologic (HOLX) gains from solid double-digit constant currency growth in core businesses like U.S. Breast Health, International and Global Molecular Diagnostics.
Hologic (HOLX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 1.75% and 1.51%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?
by Zacks Equity Research
Strength in the Breast Health business, Panther system and international business is likely to boost Hologic's (HOLX) top line in Q1.